Financial Results

For the year ended 31 December 2022



Disclaimer

Forward-looking statements

This presentation contains forward-looking statements, which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting Abcam. In some cases, you can identify forward-looking statements by the following words: "may," "might," "will," "could," "sould," "sould," "sould," "sould," "sould," "anticipate," "intend," "seek," "believe," "retimate," "predict," "potential," "continue," "continue," "contemplate," "possible" or the negative of these or other comparable terminology, although not all forward-looking statements contain these words. They are not historical facts, nor are they guarantees of future performance. Forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: challenges in implementing our strategies for revenue growth in light of competitive challenges; the development of new products or the enhancement of existing products, and the need to adapt to significant technological changes or respond to the introduction of new products by competitors to remain competitive; our customer discintent technological changes or respond to the introduction of new products by competitors to remain competitive; our customer discintent technological changes or respond to the introduction of new products by competitive challenges; the development of existing products, and the need to adapt to significant technological changes or respond to the introduction of new products by competitive challenges; the development of existing products, and the need to adapt to significant internology, with the competitive challenges or respond to the introduction of new products of new products of new products of all products of new products of all products and products of a paneling including an adapt to successfully unanage our current and potential future growth; any significant interruptions in our operations; failing to satisfy applicable quality c

Non-IFRS Measures

This presentation contains certain financial measures that are not presented in accordance with the International Financial Reporting Standards ("IFRS"), including, but not limited to, Adjusted Gross Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Return on Capital Employed ("ROCE"), Adjusted Diluted Earnings per Share, Total Constant Exchange Rate Revenue ("CER revenue"), and Free Cash Flow. These non-IFRS financial measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing Abcam's financial results. Therefore, these measures should not be considered in isolation or as an alternative to profit for the year, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. Abcam's presentation of these measures may not be comparable to similarly titled measures used by other companies. Please see the appendix to this presentation for a reconciliation of these measures to the closest comparable IFRS measure.

Third party data

Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by us. Some information contained herein has been obtained from other third-party sources and has not been independently verified such assumptions are reasonable, the sources relied on may be based on a small sample size and may fail to accurately reflect market opportunities. Moreover, no independent source has verified such assumptions, and Abcam did not commission any of the market and industry data presented herein. Industry publications, research, surveys, studies and forecasts generally state that the information they contain has been obtained from sources believed to be reliable but that the accuracy and completeness of such information is not guaranteed.


The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Abcam or the proposed offering.



Agenda



"Discoveries result from the contribution of many people and there are too few ways to recognise this."



Professor Sir Bruce Ponder

Emeritus Professor of Oncology at the University of Cambridge and former inaugural director of the Cancer Research UK Cambridge Institute

Progress happens together



Daniela Qual, PhDMcGill University

"When we first tried to get this technology off the ground, we needed special formulations and Abcam had recombinant carrier-free antibodies that were ideal because they have a much lower lot-to-lot variability. When we perform IMC™, we want to ensure we can get the exact same quality of antibodies for every experiment, so we don't have to optimize and validate our antibody batches again and again.

Using recombinant antibodies really make sense for scientists investing so much money in antibody-based technologies like IMCTM. If we run out of antibody, we don't want to have to go back to the drawing board and start everything from scratch, it just wastes time. We've tested hundreds of antibodies so far and the Abcam carrier-free recombinant antibodies have been the most reliable for us. These antibodies also consistently have a really high percentage of recovery after metal conjugation."

"For anyone interested in IMC, I highly recommend Abcam for antibodies if you are doing custom conjugations (especially their RabMab catalogue)."



Highlights



Finance

- +HSD CER revenue growth
- 21.1% Adjusted operating profit margin
- +21% Adjusted diluted EPS growth
- 8.9% Adjusted ROCE
- Global market share leader (CiteAb)
 - #1 in Ab citations
 - ~80,000 citations



Employee highlights

- Top 25% in eNPS
- Top 5% in DE&I benchmark
- EXA '22 triple award winner
- >90% employeeowners



Partners

- 18 new partner agreements
- >1,200 antibodies commercialised



ESG

- Best in class, 1st Percentile
 (Low-Risk Sustainalytics)
- MSCI "A"
- +4 FcoVadis score
- Women represent:
 - 57% Overall employees
 - 52% Managers
 - 70% Promotions
 - 44% Board of Directors






NTRK (EPR17341)

Immediately available **abcam** antibody saved **1-2 years** on development timeline for **Roche** IVD assay development

https://diagnostics.roche.com/us/en/landing-pages/ventana-pan-trk--epr17341--assay.html



Roche partnership with abcam enabled IVD product to be launched from journal publication to regulatory approval in <2-years




Attacking growth constraints



Reducing constraints has enabled in-house revenues

Revenues



1- CER results are calculated by applying prior year's actual exchange rates to this year's results









~2,000 new Abs and Ab pairs Multi-clonal introduction





BioVision integration Brickbio conjugation Proteins expansion Cell line automation



Be a leading discovery partner for BioPharma



Extending partnerships Enhancing quality validation



Be a leading digital company



Upgrades to architecture, data, and core ERP



 \rightarrow

Expansions in Singapore, Fremont, and Waltham Nasdaq listing 2023

REFINE

Improved customer experience technology

Kits manufacturing expansion and automation


Financial review


Michael Baldock, CFO





Financial highlights for 2022















ROCE

¹⁻ BioVision is reported as in-house vs. third party impacting comparability

²⁻ CER results are calculated by applying prior year's actual exchange rates to this year's results

Catalogue revenue¹








In-house catalogue sales




Key takeaways - Favourable mix shift²







Abcam In-house Catalogue revenue¹, £m



- 1- In-house catalogue revenue including BioVision (+28% on a reported basis)
- 2- CER revenue growth rates are calculated by applying prior year's actual exchange rates to this year's results



Adjusted operating expenses



2022 OpEx

- Strong cost controls² offsetting planned investments
 - Headcount investments to support in-house growth
 - Final year of ERP and increased license costs
 - A return to travel post COVID-19
- Focused on driving operating leverage consistent with 2024 goals

Adjusted Operating Expenses^{1,2}, % of Revenues



- 1- Reported adjusted operating expenses, % of reported revenues.
- 2- Pro-forma H2 2022 (assumes no revenue impact), % of reported revenues



Summary 2022

- Final installation of ERP system
- Elimination of three material weaknesses
- Ongoing gross margin growth enabled by in-house products
- OpEx is expanding adjusted operating margins













Road to 2024



FY23

- £420m £440m Reported Revenues (+15%-20% CER)
- Ongoing adj. operating profit margin expansion
- Focusing on refinement: ERP invoicing and cash collection
- US GAAP



FY24


- £450m £525m¹
- Adjusted operating profit margin >30%



Appendix




Product cohort data





FY22 breakdown by currency





Adjusted gross profit reconciliation

	Year ended 31	Year ended 31
fm	December 2022	December 2021
Adjusted gross profit	273.2	227.7
Amortisation of fair value adjustments	(2.7)	(3.1)
Reported gross profit	270.5	224.6



Adjusted operating profit reconciliation

	Year ended 31	Year ended 31
£m	December 2022	December 2021
Adjusted operating profit	76.3	60.4
Impairment of intangible asset and asset held for sale	(18.3)	(1.1)
System and process improvement costs	(6.6)	(7.0)
Amortisation of fair value adjustments	(2.7)	(3.1)
Acquistion costs	-	(8.3)
Integration and reorganisation costs	(15.7)	(4.7)
Amortisation of acquistion intangibles	(16.9)	(9.1)
Share-base payments charges	(26.2)	(20.0)
Reported operating profit	(10.1)	7.1



Free cash flow reconciliation

	Year ended 31	Year ended 31	
£m	December 2022	December 2021	
Net cash flow from operating activities	28.7	62.9	
Purchase of property, plant and equipment	(16.8)	(34.5)	
Purchase of intangible assets	(24.5)	(25.3)	
Reimbursement of leasehold improvement costs	-	13.2	
Principal and interest for lease payments	(13.4)	(10.3)	
Transfer (to) / from Escrow - future CapEx	0.3		
Free cashflow	(25.7)	6.0	



ROCE

	Year ended 31	Year ended 31
£m	December 2022	December 2021
Adjusted operating profit	76.3	60.4
Total assets	1,056.6	1,000.9
Current liabilities	(201.8)	(202.0)
Capital employed	854.8	798.9
ROCE	8.9%	7.6%



Adjusted diluted EPS

	Yea	r ended 31	Yea	ar ended 31
£m	December 2022		December 2021	
Reported operating profit		(10.1)		7.1
Impairment of intangible asset and asset held for sale		18.3		1.1
System and process improvement costs		6.6		7.0
Amortisation of fair value adjustments		2.7		3.1
Acquistion costs		-		8.3
Integration and reorganisation costs		15.7		4.7
Amortisation of acquistion intangibles		16.9		9.1
Share-base payments charges		26.2		20.0
Adjusted operating profit		76.3		60.4
Finance costs	(5.5)		(2.4)	
Profit before tax		70.8		58.0
Taxes		(13.1)		(10.8)
Net Profit		57.7		(47.2)
Adjusted Diluted Earnigs Per Share	£	0.249	£	0.206

